Replies to post #135690 on Biotech Values

[genisi]

I don't know if I want to go as far as saying this renders the BLRX PR misleading (due to claims about a novel target), but it's the kind of PR normally issued by less credible small-cap biotech firms IMHO.

When I asked I used the term 'not clear' and I'll give them the benefit of the doubt the terms 'acts via a unique mechanism of action' and 'differs from the mechanism of currently used anti hepatitis agents', because this might be correct for all we know. However, nowhere in the PR the term 'NS3/4A protease inhibitor' is mentioned and in this omission lies a possible intent to mislead. I hope to explain this to them sometime because I do appreciate the people and the company and they have been impeccable so far or I wouldn't have looked at nor touched BLRX ever.